SARS-CoV-2 outbreak in a synagogue community: longevity and strength of anti-SARS-CoV-2 IgG responses. (24th June 2021)
- Record Type:
- Journal Article
- Title:
- SARS-CoV-2 outbreak in a synagogue community: longevity and strength of anti-SARS-CoV-2 IgG responses. (24th June 2021)
- Main Title:
- SARS-CoV-2 outbreak in a synagogue community: longevity and strength of anti-SARS-CoV-2 IgG responses
- Authors:
- Gozlan, Yael
Reingold, Stephen
Koren, Ravit
Halpern, Osnat
Regev-Yochay, Gili
Cohen, Carmit
Biber, Asaf
Picard, Orit
Mendelson, Ella
Lustig, Yaniv
Mor, Orna - Abstract:
- Abstract: Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) pandemic is still ongoing along with the global vaccination efforts against it. Here, we aimed to understand the longevity and strength of anti-SARS-CoV-2 IgG responses in a small community ( n = 283) six months following local SARS-COV-2 outbreak in March 2020. Three serological assays were compared and neutralisation capability was also determined. Overall 16.6% (47/283) of the participants were seropositive and 89.4% (42/47) of the IgG positives had neutralising antibodies. Most of the symptomatic individuals confirmed as polymerase chain reaction (PCR) positive during the outbreak were seropositive (30/32, 93.8%) and 33.3% of the individuals who quarantined with a PCR confirmed patient had antibodies. Serological assays comparison revealed that Architect (Abbott) targeting the N protein LIASON ® (DiaSorin) targeting the S protein and enzyme-linked immunosorbent assay (ELISA) targeting receptor binding domain detected 9.5% (27/283), 17.3% (49/283) and 17% (48/283), respectively, as IgG positives. The latter two assays highly agreed (kappa = 0.89) between each other. In addition, 95%, (19/20, by ELISA) and 90.9% (20/22, with LIASON) and only 71.4% (15/21, by Architect) of individuals that were seropositive in May 2020 were found positive also in September. The unexpected low rate of overall immunity indicates the absence of un-noticed, asymptomatic infections. Lack of overall high correlation betweenAbstract: Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) pandemic is still ongoing along with the global vaccination efforts against it. Here, we aimed to understand the longevity and strength of anti-SARS-CoV-2 IgG responses in a small community ( n = 283) six months following local SARS-COV-2 outbreak in March 2020. Three serological assays were compared and neutralisation capability was also determined. Overall 16.6% (47/283) of the participants were seropositive and 89.4% (42/47) of the IgG positives had neutralising antibodies. Most of the symptomatic individuals confirmed as polymerase chain reaction (PCR) positive during the outbreak were seropositive (30/32, 93.8%) and 33.3% of the individuals who quarantined with a PCR confirmed patient had antibodies. Serological assays comparison revealed that Architect (Abbott) targeting the N protein LIASON ® (DiaSorin) targeting the S protein and enzyme-linked immunosorbent assay (ELISA) targeting receptor binding domain detected 9.5% (27/283), 17.3% (49/283) and 17% (48/283), respectively, as IgG positives. The latter two assays highly agreed (kappa = 0.89) between each other. In addition, 95%, (19/20, by ELISA) and 90.9% (20/22, with LIASON) and only 71.4% (15/21, by Architect) of individuals that were seropositive in May 2020 were found positive also in September. The unexpected low rate of overall immunity indicates the absence of un-noticed, asymptomatic infections. Lack of overall high correlation between the assays is attributed mainly to target-mediated antibody responses and suggests that using a single serological assay may be misleading. … (more)
- Is Part Of:
- Epidemiology and infection. Volume 149(2021)
- Journal:
- Epidemiology and infection
- Issue:
- Volume 149(2021)
- Issue Display:
- Volume 149, Issue 2021 (2021)
- Year:
- 2021
- Volume:
- 149
- Issue:
- 2021
- Issue Sort Value:
- 2021-0149-2021-0000
- Page Start:
- Page End:
- Publication Date:
- 2021-06-24
- Subjects:
- Herd immunity -- IgG antibodies -- neutralising antibodies -- SARS-CoV-2 -- sero-prevalence
Communicable diseases -- Periodicals
Epidemiology -- Periodicals
614.4 - Journal URLs:
- http://journals.cambridge.org/action/displayJournal?jid=HYG ↗
http://journals.cambridge.org/action/displayJournal?jid=HYG ↗ - DOI:
- 10.1017/S0950268821001369 ↗
- Languages:
- English
- ISSNs:
- 0950-2688
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library STI - ELD Digital Store
- Ingest File:
- 18373.xml